BioPharmX Corp fka BPMX

[Whos_Who]

In-depth review of BPX-01

BioPharmX BPMX BPX-01 Minocycline Topical Gel Shows Promise for the Treatment of Moderate-to-severe Inflammatory Acne Vulgaris
Read full in-depth article in link here

* In Study 1, BPX-01 treatment reduced P. acnes colonization by 90.9 percent, which exceeded the reduction in the vehicle control group

* In Study 2, treatment with BPX-01 2% reduced the number of inflammatory lesions by 58.5 percent, exceeding the reduction in the vehicle control group

* There was a statistically significant decrease in P. acnes during the four weeks of BPX-01 1% treatment

* When asked, “Would you consider using the study medication again?,” 86.2 percent of subjects in the BPX-01 1% group and 81.0 percent in the 2% group answered affirmatively

* Subjects also reported a high degree of satisfaction with using the product and its treatment results.

* This treatment might provide an effective new option with a favorable safety profile, a potential for high patient adherence, and avoidance of AEs associated with oral minocycline use.